glp-1/gip dual agonist weight loss The Emerging Role of GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction GLP-1 Medications for Weight Loss:
Description
& Ferrannini, E
A.HammoudR.RittigN.et al (2024)
Can I take GLP-1 and insulin together
[Google Scholar] 8
Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest
Mean body weight changes across the groups at the end of 32 weeks were: CagriSema: 15.6% Semaglutide alone: 5.1% Cagrilinitide alone: 8.1% [43] Side effects included nausea (29% of patients), diarrhea (16%) and vomiting (10%) in CagriSema treated patients
